As part of our strategy to broaden our focus beyond neuropsychiatry, we acquired Momenta Pharmaceuticals and gained full rights to an anti-neonatal Fc receptor monoclonal antibody that has the potential to address a range of serious autoantibody mediated autoimmune diseases, including certain neurologic and neuromuscular disorders. Significant unmet treatment needs remain in these disease areas, despite standard of care treatment options available.

Janssen is committed to deepening our research in neurologic and neuromuscular conditions to help address the significant unmet need for therapies and treatments for patients. This acquisition also enhanced our pathway-based research and development approach across therapeutic areas.